SCHEMBL27140494

SCHEMBL27140494

COC(=O)c1ccc(OCCCCN(C(C)C)C2CCC(OC3CC(Oc4ccc(-c5ccc6c7cnccc7n(C)c6c5)cn4)C3)CC2)cc1C(=O)OC

nearest known ligand 0.35

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FAAH O00519 7/20 0.35
PIK3CA P42336 2/20 0.31
MTOR P42345 2/20 0.31
ATM Q13315 2/20 0.31
PDE2A O00408 2/20 0.31
PDE3B Q13370 2/20 0.31
PDE3A Q14432 2/20 0.31
P2RY12 Q9H244 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27098582 1.00 FAAH (0.35) FAAHPIK3CAMTORATMPDE2A
SCHEMBL29547541 1.00 FAAH (0.35) FAAHPIK3CAMTORATMPDE2A
SCHEMBL20120577 0.82 FAAH (0.35) FAAHATM
SCHEMBL22906675 0.82 FAAH (0.35) FAAHATM
SCHEMBL29547518 0.82 FAAH (0.35) FAAHATM
SCHEMBL20128924 0.82 FAAH (0.35) FAAHATM
SCHEMBL27146379 0.81 BRD9 (0.41)
SCHEMBL29857259 0.81 BRD9 (0.41)
SCHEMBL27137835 0.81 BRD9 (0.41)
SCHEMBL27098575 0.81 BRD9 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 US disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT FAAH 4357/4885PIK3CA 2655/4885MTOR 782/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN FAAH 4345/4885PIK3CA 2277/4885MTOR 765/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT FAAH 4357/4885PIK3CA 2655/4885MTOR 782/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN FAAH 3564/4885PIK3CA 3619/4885MTOR 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.